IMS Brogan is the Canadian business unit of IMS Health, a leading provider of information services for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS Health serves leading decision-makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

At IMS Brogan, our mission is to help clients keep pace with change, adapt quickly and meaningfully to the new market realities, and respond to changes with greater precision. Along the way, we help clients improve performance and minimize marketplace risk through superior forecasting and trend analysis, market access and reimbursement consulting, customized market intelligence, and improved segmentation, messaging and sales force deployment.

Wyatt Health Management is a leading Canadian pharmaceutical reimbursement consulting firm that works to advance pharmaceutical policy and to deliver successful reimbursement strategies and tactics for our clients. We employ customized solutions and innovative techniques such as Reimbursement Communications Plans so that payers understand the real message.

Our CDR Tracker® is the most comprehensive source of information on Canada’s Common Drug Review (CDR) and provides you with what you really need to know. We have a variety of CDR Tracker® products available that can be tailored to meet your needs.

Visit us at www.wyatthealth.com and www.cdrtracker.com to learn more about us and our services.

The Pangaea Group is an extraordinary Canadian pharma consulting group that has created a network of experts/expertise in Canadian pharma. Pangaea is comprised of senior level executives with diverse industry and business experience that can provide a broad and deep understanding of the industry and its issues.

Strong relationships and a unique collaborative approach enable us to deliver exceptionally high quality results for our clients. As collaboration is key, our consultants work together and with our clients to lay a ground work that enables learning and achievement at the highest professional potential.

More information coming soon...

Health care continues to be the top issue for most Canadians who want assurances from political leaders that they will have access to quality health care when they need it. Health care officials and politicians across the country are challenged by the sustainability problem: how to pay for quality universal health care when costs are rising, and other social programs also need funding.

Governments are therefore challenged to provide the policy and regulatory environments in which public health care is delivered given finite resources and pressures on all fronts of the health care system to improve service. Increasingly, the private sector is being seen as a partner in policy development, but this requires a fine balance between public and private interest and participation that is clear, transparent and accountable.

Given the multi-jurisdictional nature of health policy and innovation across Canada, Global's Health & Life Sciences practice regularly draws upon our network of consultants across Canada to provide a federal, national or province-specific suite of services. The Health & Life Sciences team monitors, advocates, and provides strategic and tactical advice on the following issues:

• Regulatory issues, including the health product approval process and Food and Drugs Act modernization
• Public and private pricing and reimbursement policies and trends
• Intellectual property issues
• Federal/Provincial/Territorial initiatives, including the Canadian Agency for Drugs and Technologies in Health (CADTH) and Common Drug Review (CDR)
• Industrial incentive policy and marketing practice regulations
• Political and legislative initiatives

Global's Health & Life Sciences practice serves international innovative pharmaceutical companies, medical device manufacturers, health associations, non-profit health organizations and health care product manufacturers.

The JBL Group is a multi-faceted consulting firm, specializing in Health Policy, Government Affairs and Market Access for the health care industry in Canada and abroad. We offer our clients a team of highly qualified professionals who bring to each challenge a wealth of experience in resolving complex business issues, from providing top-level strategic advice to hands-on program management and implementation. Our expertise and complete knowledge of the health and pharmaceutical industry enables us to fully understand our clients' needs and deliver the results they expect.

PDCI Market Access (PDCI) is a leading pharmaceutical pricing and reimbursement (P&R) consultancy based in Ottawa and Toronto. Established in 1996, the firm features a senior team of bilingual market access professionals with extensive experience assisting clients navigate the complex P&R challenges facing Canadian pharmaceutical manufacturers. PDCI develops successful P&R strategies and prepares comprehensive submissions to CDR, pCODR, public & private payers and the PMPRB. The firm's senior consultants facilitate meetings with CDR/payers/PMPRB, negotiate product listing agreements (PLAs) and resolve pricing compliance issues with the PMPRB. PDCI maintains databases of international pharmaceutical prices and provincial drug claims and costs.